Camford Capital: Funding, Team & Investors

Loading organizations...

Camford Capital: Funding, Team & Investors | Startup Intros

Investment Activity

Camford Capital has 7 tracked investments across 6 companies. The latest tracked deal is $66.0M Series B in Totus Medicines in December 2023.

Investments

6 companies

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Dec 1, 2023	Totus Medicines	$66.0M Series B	John Hamer	Zachary Bogue, Dcvc (data Collective), Dimension Capital, Pivotal BioVenture Partners, The Column Group, Northpond Ventures, University OF Minnesota
Jul 1, 2023	SURGE Therapeutics	$32.0M Series B	Bioluminescence Ventures	5AM Ventures, Arix Bioscience, F Prime Capital, Intuitive Ventures, 8VC, Alumni Ventures, Cancer Research Institute, KDT Ventures, Khosla Ventures, Piedmont Capital, Pitango HealthTech
May 10, 2023	Lavita	$5.0M Seed	Camford Capital	—
Oct 1, 2022	SURGE Therapeutics	$26.0M Series A	Camford Capital	Bioluminescence Ventures, Intuitive Ventures, 8VC, Alumni Ventures, Cancer Research Institute, Khosla Ventures, Pitango HealthTech
Jun 1, 2022	Carbon Biosciences	$38.0M Series A	Agent Capital	Hiromichi Kimura, Astellas Venture Management, Martin Mense, David Steinberg, Derek Yoon, University OF Tokyo Edge Capital
Jun 1, 2021	Strand Therapeutics	$52.0M Series A	—	FPV Fund, Kinnevik, Playground Global, ANRI, Beigene, Redmile Group
Dec 10, 2020	CG Oncology	$47.0M Series D	Mutsuo Kanzawa	ORI Healthcare Fund, Perseverance Capital Management